Plunkett Research Online: Amicus Therapeutics Inc

AMICUS THERAPEUTICS INC (FOLD:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Amicus Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of novel treatments for patients living with rare metabolic diseases. The firm’s primary product is migalastat HC1, an oral precision medicine for people with Fabry disease who have .....



Amicus Therapeutics Inc
Ticker: FOLD
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 609 662-2000
Fax: 609 662-2001
Address: 1 Cedar Brook Drive
Cranbury, NJ 08512 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceutical Preparation Manufacturing
ContactsDescription
John CrowleyCEO/Chairman of the Board/Director
William BairdCFO
See More
Amicus Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of novel treatments for patients living with rare metabolic diseases. The firm’s primary product is migalastat HC1, an oral precision medicine for people with Fabry disease who have .....See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201720162015201420132012
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
migalastat HC1
GALAFOLD
ATB200/AT2221
Chaperone-Advanced Replacement Therapy
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: